Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Therapies for dopaminergic-induced dyskinesias in Parkinson disease.

Gottwald MD, Aminoff MJ.

Ann Neurol. 2011 Jun;69(6):919-27. doi: 10.1002/ana.22423. Review.

PMID:
21681795
[PubMed - indexed for MEDLINE]
2.

Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.

Encarnacion EV, Hauser RA.

Eur Neurol. 2008;60(2):57-66. doi: 10.1159/000131893. Epub 2008 May 15. Review.

PMID:
18480609
[PubMed - indexed for MEDLINE]
3.

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U.

Mov Disord. 2001 May;16(3):515-20.

PMID:
11391748
[PubMed - indexed for MEDLINE]
4.

[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].

Damier P, Tremblay L, Féger J, Hirsch EC.

Rev Neurol (Paris). 2000 Mar;156(3):224-35. Review. French.

PMID:
10740093
[PubMed - indexed for MEDLINE]
5.

Therapies for dopaminergic-induced dyskinesias in Parkinson disease.

Ponsford JR.

Ann Neurol. 2011 Oct;70(4):667; author reply 667-8. doi: 10.1002/ana.22604. No abstract available.

PMID:
22028228
[PubMed - indexed for MEDLINE]
6.

Dyskinesia: L-dopa-induced and tardive dyskinesia.

Rascol O, Fabre N.

Clin Neuropharmacol. 2001 Nov-Dec;24(6):313-23. Review.

PMID:
11801806
[PubMed - indexed for MEDLINE]
7.

Preventing levodopa-induced dyskinesias.

Olanow CW, Obeso JA.

Ann Neurol. 2000 Apr;47(4 Suppl 1):S167-76; discussion S176-8. Review.

PMID:
10762145
[PubMed - indexed for MEDLINE]
8.

Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.

Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.

Neuropharmacology. 2010 Jan;58(1):286-96. doi: 10.1016/j.neuropharm.2009.06.030. Epub 2009 Jul 2.

PMID:
19576910
[PubMed - indexed for MEDLINE]
9.

Medical management of levodopa-associated motor complications in patients with Parkinson's disease.

Jankovic J, Stacy M.

CNS Drugs. 2007;21(8):677-92. Review.

PMID:
17630819
[PubMed - indexed for MEDLINE]
10.

Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M; 056 Study Group.

Mov Disord. 2006 Nov;21(11):1844-50.

PMID:
16958094
[PubMed - indexed for MEDLINE]
11.

[Management of levodopa-induced dyskinesia].

Rascol O, Ferreira JJ, Payoux P, Brefel-Courbon Ch, Montastruc JL.

Rev Neurol (Paris). 2002 Dec;158 Spec no 1:S117-24. Review. French.

PMID:
12690671
[PubMed - indexed for MEDLINE]
12.

[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].

Rascol O, Brefel-Courbon C, Blin O.

Therapie. 1998 Jan-Feb;53(1):43-8. French.

PMID:
9773099
[PubMed - indexed for MEDLINE]
13.

The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.

Merims D, Ziv I, Sherki Y, Djaldetti R, Melamed E.

Neurol Neurochir Pol. 2001;35 Suppl 3:65-8.

PMID:
12001656
[PubMed - indexed for MEDLINE]
14.

Levodopa-induced dyskinesias.

Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG.

Mov Disord. 2007 Jul 30;22(10):1379-89; quiz 1523. Review.

PMID:
17427940
[PubMed - indexed for MEDLINE]
15.

A walk through the management of Parkinson s disease.

Lim E.

Ann Acad Med Singapore. 2005 Mar;34(2):188-95. Review.

PMID:
15827667
[PubMed - indexed for MEDLINE]
Free Article
16.

Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.

Chase TN.

Neurology. 1998 May;50(5 Suppl 5):S17-25. Review.

PMID:
9591518
[PubMed - indexed for MEDLINE]
17.

Treatment of Parkinson's disease: levodopa as the first choice.

Katzenschlager R, Lees AJ.

J Neurol. 2002 Sep;249 Suppl 2:II19-24. Review.

PMID:
12375059
[PubMed - indexed for MEDLINE]
18.

[Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].

Destée A, Bordet R.

Rev Neurol (Paris). 2002 Dec;158 Spec no 1:S69-82. Review. French.

PMID:
12690666
[PubMed - indexed for MEDLINE]
19.

Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias.

Follett KA.

Neurosurg Focus. 2004 Jul 15;17(1):E3. Review.

PMID:
15264772
[PubMed - indexed for MEDLINE]
20.

Role of dopamine receptor agonists in the treatment of early Parkinson's disease.

Bonuccelli U, Del Dotto P, Rascol O.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S44-53. doi: 10.1016/S1353-8020(09)70835-1. Review.

PMID:
20123557
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk